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Potential of interferon-c-inducible protein 10
in improving tuberculosis diagnosis in
HIV-infected patients
To the Editors:
In patients latently infected with Mycobacterium tuberculosis,
immunosuppression significantly augments the risk of progres-
sion to active tuberculosis (TB) and TB is still one of the most
frequent opportunistic infections worldwide. Prevention of TB
in HIV-positive patients using the tuberculin skin testing (TST)
followed by targeted preventive treatment is an effective
strategy, but has thus far shown limited clinical success, in part
due to the lack of a reliable test for latent TB infection (LTBI) [1].
Interferon (IFN)-c release assays (IGRAs) have shown great
potential in the improvement of LTBI diagnosis, but the tests
perform suboptimally in immunocompromised populations.
We and others have previously shown that HIV-positive
patients have high rates of indeterminate QuantiFERON1-TB
Gold In-Tube test (QFT-IT) results and that this, at least in part,
is due to low CD4 T-cell count [2–4].
We and others have also shown that IFN-c-inducible protein 10
(IP-10/CXCL-10) is an alternative biomarker may improve
immunodiagnosis of M. tuberculosis infection. IP-10 is induced
specifically and in large quantities upon in vitro stimulation of
whole blood with M. tuberculosis-specific antigens. We have
developed an IP-10 based test [5] and shown that the IP-10 test
performs comparably to the QFT-IT in adult patients with
intact immune function [6].
We compared the sensitivity of an IP-10 based test with the
QFT-IT for diagnosing M. tuberculosis infection in HIV-negative
and HIV-positive patients with culture-confirmed active
pulmonary tuberculosis (PTB). 300 patients newly diagnosed
with PTB were recruited prospectively through the National
Tuberculosis and Leprosy Programme (Mwanza, Tanzania).
Blood was drawn for IGRA and HIV testing, and CD4 cell
counts. Sputum was collected for microscopy and M. tubercu-
losis culture. Patients .15 yrs of age with a positive sputum
culture result were enrolled. All HIV-positive patients were
newly diagnosed in the study context. A detailed description
of recruitment, testing and sample handling has been
published previously [3]. After QFT-IT testing, supernatants
were frozen at -80uC. 1 yr later, samples were thawed and
analysed for IP-10 using xMAP technology on the Luminex
platform (Luminex Corp., Austin, TX, USA) as described
previously [5]. Algorithms for interpretation of IP-10 test
results have been developed previously using receiver operat-
ing characteristic analysis [5]; however, the mitogen cut-off
was chosen arbitrarily (see online supplement 1). One IU
corresponds to 50 pg IFN-c. In the literature, there is a lack of
consensus on how to present IGRA sensitivity and specificity:
including or excluding indeterminate results. We suggest the
designations ‘‘sensitivity’’ for calculation after exclusion of
indeterminate results, and ‘‘positivity rate’’ for calculation
amongst all possible test outcomes. High rates of indetermi-
nate results (i.e. low positivity rate) mainly affect usability and
cost-effectiveness, and may impair the feasibility of imple-
menting the test in severely immunocompromised individuals.
Positivity rate was calculated among all possible tests out-
comes (i.e. including indeterminate results), whereas sensitiv-
ity was calculated after exclusion of indeterminate test results.
All comparisons were done using nonparametric paired tests.
A p-value f0.05 was considered significant. Permission to
conduct the study was granted by the ethics committee of the
National Institute for Medical Research (Mwanza, Tanzania)
and was approved by The Danish National Committee on
Biomedical Research Ethics (Copenhagen, Denmark; reference
2005-7041-57).
HIV-negative (n592) and HIV-positive (n565) patients were
included in the study. HIV-positive patients were older, had
lower CD4 cell counts and were more likely to be female
(p,0.05 for all, see online supplement 2). The IP-10 test had
comparable positivity rate and sensitivity to the QFT-IT in both
HIV-positive and HIV-negative patients. Positivity rate was
lower and indeterminate rate higher in HIV-positive patients
for both tests, while there was no significant difference in
sensitivity for either test (table 1).
Impaired performance of the QFT-IT in HIV-positive patients
with a low CD4 cell count has been well documented and we
have previously demonstrated that QFT-IT sensitivity
decreases with decreasing CD4 cell count in HIV-positive
patients, which is mediated by an increasing proportion of
indeterminate results. Interestingly, for the IP-10 test, we found
no such trend with CD4 cell count for rate of positive (p50.44)
or for indeterminate (p50.55) results (fig. 1). Another recent
study in HIV-infected patients with active TB reported that,
while QFT-IT yielded indeterminate results when CD4 cell
count was ,200 cells?mL-1, an IP-10-based test yielded inde-
terminate results only when CD4 cell count was ,50 cells?mL-1
[4]. Thus, it seems that IP-10 is not, or at least is much less,
affected by CD4 cell count than is the QFT-IT. Although IFN-c
is directly involved in inducing IP-10 production, IP-10 is
produced primarily by the monocyte and might be induced by
CD4 T-cell- and IFN-c-independent pathways (e.g. induction
This article has supplementary material available at www.erj.ersjournals.com
1488 VOLUME 36 NUMBER 6 EUROPEAN RESPIRATORY JOURNAL
by other cytokines) [7]. We found no effect of monocyte count
on IP-10 test performance in either HIV-positive or -negative
patients (data not shown). Another possible explanation for the
finding is the larger amounts of biomarker produced, which
may render an IP-10-based test less sensitive to the effect of
immune suppression. Antigen-induced IP-10 levels were 21-
fold higher than IFN-c (interquartile range 7–48; p,0.001).
Lastly, the mitogen cut-off was rather low, giving less
indeterminate IP-10 test results and, thereby, possibly obscur-
ing CD4 dependency. However, increasing the mitogen cut-off
did not change these findings (data not shown). We found no
further connection between clinical characteristics (listed in
online supplement 2) and indeterminate or false negative
results by either test.
Agreement between the tests was 0.73 (k50.67) for HIV-
negative and 0.78 (k50.60) for HIV-positive patients (online
supplement 3). Combining the tests significantly increased
sensitivity to 96% in HIV-negative and 88% in HIV-positive
patients (table 1). We and others have found a similar
improvement in sensitivity among patients from low-endemic
setting without a compromise in specificity [8, 9]. Thus,
combining tests appears to be a feasible way to improve
performance of the antigen-specific assays. We found no
connection between clinical characteristics (listed in online
supplement 2) and discordant test results.
It is important to remember that the diagnostic sensitivity
obtained in a population with active and severe TB may be
lower than the sensitivity obtained among otherwise healthy
individuals with LTBI. Also, a limitation of the present study is
the lack of a control group, which prevents estimation of
specificity. None of the tests discriminates between active TB
and LTBI and, given the prevalence of LTBI in the background
population, we could not identify a valid control group in this
setting. Inclusion of a control group from another geographic
region would not have been a valid approach due to potential
influences of genetic background, comorbidity, nutritional
status, etc. However, a very high specificity of both QFT-IT
and the IP-10 test has been convincingly demonstrated in
healthy, unexposed individuals from low-endemic regions.
Unfortunately, TST was not performed in this study population.
TABLE 1 Distribution of QuantiFERON1-TB Gold In-Tube
(QFT-IT) and interferon-c-inducible protein
(IP)-10 test results and comparison between
tests
Test result Single-marker tests Combined test
IP-10 test# QFT-IT"
HIV-negative+
Positive 75 (82; 72–89) 74 (80; 71–88) 86 (93; 88–99)##
Sensitivity 86 (79–93) 88 (81–95) 96 (91–99)##
Negative 12 (13; 7–22) 10 (11; 5–19) 4 (4; 0–9)##
Indeterminate 5 (5; 2–12) 8 (9; 4–16) 2 (2; 0–5)""
HIV-positive1
Positive 41 (63; 50–75)e 41 (63; 50–75)e 46 (71; 60–82)##
Sensitivity 76 (65–87) 82 (74–95) 88 (80–97)##
Negative 13 (20; 11–32) 9 (14; 7–25) 6 (9; 2–16)++
Indeterminate 11 (17; 9–28)e 15 (23; 14–35)e 13 (20; 10–30)
Data are presented as n (%; 95% CI) or % (95% CI). Sensitivity was calculated
after excluding indeterminate results. Algorithms for test results can be seen in
online supplement 1. In the combined approach, the test was deemed positive
if either test was positive, negative if both tests were negative and indeterminate
if one test was indeterminate and the other was negative. All p-values were
calculated using McNemar’s test. #: cut-off 673 pg?mL-1, as determined in [5];
": cut-off 0.35 IU?mL-1 (17.5 pg?mL-1); +: n592; 1: n565; e: p,0.05 compared
with HIV-negative patients; ##: p,0.05 compared with either single-marker test;
"": p,0.05 compared with the QFT-IT alone; ++: p,0.05 compared with the
IP-10 test alone.
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FIGURE 1. Influence of CD4 cell count on performance of the a) QuantiFERON1-TB Gold In-Tube (&: positive results (p50.05); &: negative results (p50.99);
h: indeterminate results (p50.04)) and b) interferon-c-inducible protein 10 tests (&: positive results (p50.44); &: negative results (p50.72); h: indeterminate results
(p50.55)) in HIV-positive patients. p-values are for Cochrane–Armitage test for trend. Test results were grouped by the individual number of CD4 cells?mL-1. The numbers
of patients in each CD4 cell group were as follows. 0–99 cells?mL-1: n55; 100–199 cells?mL-1: n516; 200–349 cells?mL-1: n524; 350–499 cells?mL-1: n57; .500 cells?mL-1:
n513. a) Modified from [3]. c
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In conclusion, the IP-10 test performs with equal sensitivity to
the QFT-IT in a TB/HIV-endemic setting. Combining the tests
significantly improves sensitivity, even in HIV-positive
patients. The IP-10 test seems less affected by a low CD4 cell
count than the QFT-IT. Further approaches for improvement of
TB diagnosis are needed, especially in TB/HIV-endemic
settings, and the IP-10 biomarker represents a promising
example.
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New insight into extremely drug-resistant tuberculosis:
using atomic force microscopy
To the Editors:
We have recently documented the emergence of new forms of
resistant tuberculosis (TB) bacilli (totally drug resistant (TDR)-
TB or extremely drug-resistant (XXDR)-TB strains) among
multidrug-resistant (MDR)-TB patients [1]. XXDR-TB defines
any case of TB with resistance to all first- and second-line anti-
TB drugs whose smears and cultures remain positive despite
prolonged therapy [1–3]. At the cellular level of XXDR-TB
strains, adaptation was observed and evaluated using trans-
mission electron microscopy (TEM) [4, 5]. In the exponential
phase, three different cell populations were clearly distin-
guished: one displayed an ordinary pattern (70–80%), one
exhibited a round or oval shape (15–20%), and the third
displayed an extraordinarily thick cell wall (21–26 nm) with
features similar to stationary or anaerobic dormant bacilli (5–
7%) [3, 4]. These adapted forms were detected in all XXDR-TB
isolates, irrespective of their super families or genotype
patterns. We tried to evaluate the different cell population of
XXDR-TB strains in comparison to susceptible cells using
atomic force microcsopy (AFM). To achieve this goal, we
included sputum and culture positive specimens of the same
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